Loading...
Loading...
According to a research report published this morning, J.P. Morgan has lowered Illumina's
ILMN PT from $70 to $55.
J.P. Morgan said in the report, "Following the Q1 pre-announcement, in which ILMN disclosed preliminary revenue assumptions (see our initial take here), full quarterly results offered few surprises, with non-GAAP GMs of 69% roughly in line with our projection (of 69.4%), while non-GAAP EPS of $0.36 exceeded both JPMe (of $0.30) and the Street (at $0.32). With the $51 Roche tender offer now officially expired, however, the focus shifts to execution and visibility in the back half of the year, and to a lesser extent, capital deployment (i.e., $250M buyback announced, continued commentary around M&A)."
J.P. Morgan maintains its Overweight rating on Illumina, which closed yesterday at $43.90.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in